He advised the tariff impact would be low – “a low single-digit-million euro impact on Healthineers’ results this year,” said the news wire.

“When it stays in this range it won’t be a catastrophe, but of course the topic is very, very regrettable because it significantly impairs global trade,” he said.

As of 2017, Healthineers had 23 U.S. plants and sites, with another 17 in Europe, Middle East and Africa, and the Asia-Pacific region housing 11.

In April, Siemens Healthineers installed the first Atellica Solution immunoassay and clinical chemistry analyzers with Aptio Automation in the U.S. at Access Medical Laboratories in Jupiter, Florida.

“They needed a solution that could grow with them as their testing volume increased. Particularly for immunoassay testing, they wanted a system with the capacity to double their testing output,” Joe Amodeo, marketing manager of laboratory diagnostics in North America at Siemens Healthineers, told HCB News. “They were also interested in securing automation for as many testing disciplines as possible. Aptio Automation allows them to automate from beginning to end, not only for their chemistry and immunoassay testing on the Atellica Solution, but also for many other testing needs, including some third-party analyzers.”

Atellica was recently installed at LBM Bioesterel in France, Arcispedale S. Maria Nuova in Italy and Friarage Hospital in the United Kingdom, motivated by its flexibility for automating redundant and complex procedures to simplify testing workflows and to grow patient testing capacity.

The strong performance of Atellica and as well as the the overall strength of the Siemens Healthineers performance is one reason that its shares roared up after its IPO March 15.

The price at the IPO was in the lower half of its guidance range of 26 to 31 euros.

Siemens raised 4.2 billion euros ($5.2 billion) from the offering, Germany's second largest IPO in almost 20 years.

The Healthineers stock closed at 38.10 euros on Nov 7.

Back to HCB News

Business Affairs Homepage